Clinical trial

Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial

Name
0911-51
Description
The standard approach to sedation in endoscopic retrograde cholangiopancreatography (ERCP) involves the use of benzodiazepines and opiates to achieve a moderate depth of sedation. There is data to suggest supplementing this regimen with gabapentin may lead to reduced pain, higher patient satisfaction and lower opiate requirements. The investigators are conducting a clinical trial to study this hypothesis.
Trial arms
Trial start
2010-04-01
Estimated PCD
2011-12-01
Trial end
2011-12-01
Status
Completed
Treatment
Gabapentin
gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
Arms:
Gapabentin
Standard sedation regimen
Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
Arms:
Standard sedation
Size
56
Primary endpoint
Dosing Requirements
At time of discharge post-procedure
Eligibility criteria
Inclusion Criteria: * Male or female patients \>18 years of age referred to IUMC for first-time ERCP procedure. Exclusion Criteria: 1. Pregnant women 2. age \<18 years 3. Incarcerated individuals 4. Patients currently taking or having taken gabapentin or pregabalin within the last 3 months 5. Patients unable to give informed consent 6. Patients not able to fill out visual analog scales for pain, nausea and anxiety or unable to fill out survey regarding procedural satisfaction. 7. High risk patients for anesthesia: home oxygen, class III or IV heart failure, sleep apnea (on CPAP/BiPAP at home), or ASA class \> 3. 8. Patients undergoing general anesthesia for their ERCP procedure 9. Patients receiving propofol sedation for their ERCP procedure
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 56, 'type': 'ACTUAL'}}
Updated at
2023-09-28

1 organization

1 product

1 indication

Organization
Indiana University
Product
Gabapentin